Genomic Correlations for Clinical Outcomes in HER2-positive Advanced Gastric Cancer Treated Using Trastuzumab-based Therapy
Anticancer Research · 2025
DOI: 10.21873/anticanres.17901 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2025. Verfasst von Sun Young Lee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Stomach Neoplasms, Trastuzumab, Erb-b2 Receptor Tyrosine Kinases, Antineoplastic Combined Chemotherapy Protocols.
Abstract (Originalsprache)
BACKGROUND/AIM: Although trastuzumab-based chemotherapy improves survival in HER2-positive advanced gastric cancer, some patients demonstrate suboptimal efficacy and limited response durations. We examined the relationship between clinical outcomes and genomic features, including co-mutations and the length of the ERBB2-amplified segment. PATIENTS AND METHODS: We retrospectively analyzed 151 patients who had received first-line trastuzumab-based chemotherapy. Targeted next-generation sequencing was employed to assess genomic alterations. Progression-free survival (PFS) was defined as time from treatment initiation to disease progression or death. RESULTS: The median patient age was 62 years, and 73.5% of patients were male. The median follow-up period was 45.8 months, and the median PFS was 8.2 months [95% confidence interval (CI)=6.5-9.4]. Patients with a focal amplification of ERBB2 (≤879 Kb) had significantly longer PFS compared to those with non-focal amplifications (>879 Kb) (10.1 vs. 6.1 months; log-rank p=0.007). NOTCH3 alterations were associated with shorter PFS (log-rank p=0.003). Multivariate analysis confirmed that ERBB2 focal amplification is an independent prognostic factor associated with improved prognosis, whereas NOTCH3 alterations serve as an independent prognostic factor for poorer outcomes. CONCLUSION: ERBB2 focal amplification is associated with improved outcomes in trastuzumab-treated patients with HER2-positive gastric cancer, whereas NOTCH3 alterations predict a poor prognosis. These genomic features may support risk stratification and therapeutic decisions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; miniryu@amc.seoul.kr.
Zitieren
APA
Lee, S. Y., Hyung, J., Kim, H. D., Lee, H., Moon, M., Park, Y. S., & Ryu, M. H. (2025). Genomic Correlations for Clinical Outcomes in HER2-positive Advanced Gastric Cancer Treated Using Trastuzumab-based Therapy. Anticancer Research. https://doi.org/10.21873/anticanres.17901
Vancouver
Lee SY, Hyung J, Kim HD, Lee H, Moon M, Park YS, et al. Genomic Correlations for Clinical Outcomes in HER2-positive Advanced Gastric Cancer Treated Using Trastuzumab-based Therapy. Anticancer Research. 2025. doi:10.21873/anticanres.17901
BibTeX
@article{Lee2025,
author = {Lee, Sun Young and Hyung, Jaewon and Kim, Hyung-Don and Lee, Hyungeun and Moon, Meesun and Park, Young Soo and Ryu, Min-Hee},
title = {Genomic Correlations for Clinical Outcomes in HER2-positive Advanced Gastric Cancer Treated Using Trastuzumab-based Therapy},
journal = {Anticancer Research},
year = {2025},
doi = {10.21873/anticanres.17901}
}
EUVIMED